Effect of statin for CKD with hyperlipidemia

Effect of statin for CKD with hyperlipidemia - Ibaraki Pitavastatin or rosuvastatin renal function improvement trial: i-PLUM

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006600

Enrollment

100

Registered

2011-11-01

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

Treat with pitavastatin (2mg daily) for 52 weeks Treat with rosuvastatin (2.5mg daily) for 52 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: eGFR < 60mL/min/1.73m2 Patient for doing nourishment instruction with CKD guideline more than one month, TC>180mg/dL or LDL-C>100mg/dL after diet therapy

Exclusion criteria

Exclusion criteria: 1. Patient taking HMG-CoA reductase inhibitors 2. Patient taking cyclosporin. 3. Patient taking glucocorticoid 4. eGFR<15, or liver dysfunction 5. Patient with nephrotic syndrome 6. Patients with malignacy 7. Pregnant or nursing woman 8. Familial hypercholesteremia 9. LDL-C>200mg/dL 10. Patient who donot give written informed consent 11.Patient with diagnosis inadequacy for doctor in attendance

Design outcomes

Primary

Measure	Time frame
Percent change of estimated GFR	—

Secondary

Measure	Time frame
1. Changes of plasma and urine parameters related to renal function and dyslipidemia (T-Chol, TG, HDL-C, LDL-C, UN, Cr, TP, Alb, hs-CRP, cystatin C, HbA1C, AST, ALT, gamma-GTP, CK, urinary protein, urine protein creatinine ratio) 2. Adverse reactions	—

Countries

Japan

Contacts

Public ContactChie Saito

University of Tsukuba Nephrology

chie.saito@md.tsukuba.ac.jp029-853-3202

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026